Journals / Epilepsi / 2016 / Cilt: 22 - Sayı: 2

Neurocognitive Evaluation in Epilepsy Patients Treated with Monotheraphy: A Preliminary Report

Monoterapi Alan Epilepsi Hastalarında Nöropsikolojik Profilin Değerlendirilmesi: Bir Ön Çalışma

Journal
Epilepsi
Pages
51–54
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The lack of difference in cognitive findings between CBZ and VPA groups suggests that when beginning treatment, the choice of antiepileptic drug should be determined based on type of seizure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The present study evaluated neurocognitive profile of patients with epilepsy treated with carbamazepine (CBZ) and valproic acid (VPA).
📊
Key Findings & Data:Methods: Epilepsy patients who were treated with CBZ and VPA at outpatient clinic between 2013 and 2015 and a healthy control group were included in the study.
💡
Conclusion & Impact:Conclusion: The lack of difference in cognitive findings between CBZ and VPA groups suggests that when beginning treatment, the choice of antiepileptic drug should be determined based on type of seizure.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The present study evaluated neurocognitive profile of patients with epilepsy treated with carbamazepine (CBZ) and valproic acid (VPA). Methods: Epilepsy patients who were treated with CBZ and VPA at outpatient clinic between 2013 and 2015 and a healthy control group were included in the study. Neurocognitive findings (mini-mental state examination [MMSE], clock-drawing test, verbal and visual memory tests, digit span test, verbal fluency test) of the groups were compared. Results: Thirty patients with epilepsy treated with CBZ (n=17) and VPA (n=13) and healthy control group (n=21) were included in the study. Clock drawing test score was lower in CBZ group (p=0.024) and forward digit span test score was lower in VPA group (p=0.039) than the healthy controls. There was no significant difference in neurocognitive findings between CBZ and VPA groups. Conclusion: The lack of difference in cognitive findings between CBZ and VPA groups suggests that when beginning treatment, the choice of antiepileptic drug should be determined based on type of seizure.

Özet

Amaç: Bu çalışmada, parsiyel veya jeneralize epilepsi tanısı alan karbamazepin (KBZ) veya valproik asit (VPA) kullanan olguların nörokognitif profilleri değerlendirildi. Gereç ve Yöntem: Çalışmaya 2013–2015 yılları arasında epilepsi polikliniğine başvuran, KBZ veya VPA monoterapisi alan epilepsi hastaları ve sağlıklı kontrol grubu alındı. Sağlıklı kontrol, KBZ ve VPA gruplarının nörokognitif verileri birbiriyle karşılaştırıldı (Minimental durum testi, saat çizme testi, sözel ve görsel bellek testleri, sayı menzili testi, sözel akıcılık testi). Bulgular: Çalışmaya toplam 30 epilepsi olgusu (17 KBZ, 13 VPA kullanan), 21 sağlıklı kontrol grubu alındı. KBZ kullanan grupta saat çizme testinde (p=0.024), VPA grubunda ise ileri sayı menzilinde (p=0.039) kontrol grubuna göre farklılık saptandı. VPA ve KBZ grubu birbiriyle karşılaştırıldığında tüm nörokognitif testler açısından anlamlı farklılık gözlenmedi. Sonuç: KBZ ve VPA grupları arasında kognitif açıdan bir fark olmaması, tedaviye başlarken ilaç seçiminin nöbet tipine göre belirlenmesi gerektiğini göstermiştir.

🔖

Cite This Article

EVLİCE, A., DEMİR, T., BOZDEMİR, H., ASLAN, K. (2016). Neurocognitive Evaluation in Epilepsy Patients Treated with Monotheraphy: A Preliminary Report. Epilepsi, Cilt: 22 - Sayı: 2, 51–54. https://ajindex.com/articles/160709

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Meador KJ, Gilliam FG, Kanner AM, Pellock JM. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 2001;2(4):1–17.
  2. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007;17:413–25.
  3. Hirsch E, Schmitz B, Carreño M. Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurol Scand Suppl 2003;180:23– 32. Keskinoglu P, Ucku R, Yener G, Yaka E, Kurt P, Tunca Z. Reliability and validity of revised Turkish version of Mini Mental State Examination (rMMSE-T) in community-dwelling educated and uneducated elderly. Int J Geriatr Psychiatry 2009;24(11):1242–50. Wechsler D. Wechsler adult intelligence scale. 3rd ed. (WAIS Ш): Test Manual 3rd ed. New York: Psychological corporation; 1997. Lezak MD. Neuropsychological assesment. Oxford, UK: Oxford Univesity Press; 1995. Leazak D. Neuropsychological assesment. New York: New York Univesity Press; 1983.
  4. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36(6):378–84.
  5. Prevey ML, Delaney RC, Cramer JA, Cattanach L, Collins JF, Mattson RH. Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996;53(10):1008–16.
  6. Gerton BK, Brown TT, Meyer-Lindenberg A, Kohn P, Holt JL, Olsen RK, et al. Shared and distinct neurophysiological components of the digits forward and backward tasks as revealed by functional neuroimaging. Neuropsychologia 2004;42(13):1781–7. Aleman A, van’t Wout M. Repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex disrupts digit span task performance. Neuropsychobiology 2008;57(1- 2):44–8.
  7. Freedman M, Leach L, Kaplan E, Winocur G, Shulman K, Delis DC. Clock Drawing; A Neuropsychological Analysis. New York: Oxford University Press, 1994.